Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China

Wu, Xiaohua; Sun, Yang; Yang, Hongying; Wang, Jing; Lou, Hanmei; Li, Dan; Wang, Ke; Zhang, Hui; Wu, Tao; Li, Yuzhi; Wang, Chunyan; Li, Guiling; Wang, Yifeng; Li, Dapeng; Tang, Ying; Pan, Mei; Cai, Hongyi; Wang, Weihu; Yang, Bing; Qian, Hua; Tian, Qiuhong; Yao, Desheng; Cheng, Ying; Wei, Bing; Li, Xiumin; Wang, Tao; Hao, Min; Wang, Xiaohong; Wang, Tiejun; Ran, Juntao; Zhu, Hong; Zhu, Lijing; Liu, Xianling; Li, Yunxia; Chen, Lihong; Li, Qingshan; Yan, Xiaojian; Wang, Fei; Cai, Hongbing; Zhang, Yunyan; Liang, Zhiqing; Liu, Funan; Huang, Yi; Xia, Bairong; Qu, Pengpeng; Zhu, Genhai; Chen, Youguo; Song, Kun; Sun, Meili; Chen, Zhengzheng; Zhou, Qiang; Hu, Lina; Abulizi, Guzhalinuer; Guo, Hongyan; Liao, Sihai; Ye, Yijing; Yan, Ping; Tang, Qiu; Sun, Guoping; Liu, Ting; Lu, Dongmei; Hu, Mingxiu; Wang, Zhongmin M; Li, Baiyong; Xia, Michelle

doi:10.1016/s0140-6736(24)02135-4

The Lancet

2024

DOI: 10.1016/s0140-6736(24)02135-4

|View full text |Cite

Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China

Xiaohua Wu,

Yang Sun,

Hongying Yang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Embracing more treatment choices for metastatic, recurrent, or persistent cervical cancer

Sun,

2024

The Lancet

View full text Add to dashboard Cite

Embracing more treatment choices for metastatic, recurrent, or persistent cervical cancer

Sun,

2024

The Lancet

View full text Add to dashboard Cite

Cadonilimab is effective and safe in recurrent cervical cancer

Romero

2024

Nat Rev Clin Oncol

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China

Cited by 2 publications

References 24 publications

Embracing more treatment choices for metastatic, recurrent, or persistent cervical cancer

Embracing more treatment choices for metastatic, recurrent, or persistent cervical cancer

Cadonilimab is effective and safe in recurrent cervical cancer

Contact Info

Product

Resources

About